Investors Seek GLP-1 Alternatives After Nausea Hurdles
A new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
134 articlesA new wave of weight-loss therapies aims to beat current GLP-1 drugs by reducing side effects and daily dosing. Inves...
A smaller biotech is stealing headlines in 2026 by delivering strong trial results and strategic collaborations. This...
Investors are zooming in on InspireMD after its Q1 2026 earnings. This detailed look breaks down the numbers, the pro...
A CEO’s large stock sale can spark questions about a company’s trajectory. This guide breaks down what genomics sells...
Two affordable biotech names are drawing attention for potential low-beta growth as AI-driven tools reshape pipelines...
Perceptic, a London-founded startup formed by former Palantir Life Sciences executives, launches from stealth with a ...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
The race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
Eli Lilly kicked off 2026 with blockbuster sales and higher guidance, reigniting talk of a path to $1800 for Lilly st...
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
A de-extinction startup says it hatched 26 live chicks in a lab using a synthetic eggshell, spotlighting frontier bio...
A clear, investor-friendly look at Iridex's Q1 2026 performance and what it could mean for the full year. Learn the n...